ASX:NEU Neuren Pharmaceuticals (NEU) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Neuren Pharmaceuticals Stock (ASX:NEU) 30 days 90 days 365 days Advanced Chart Ad DTIWhen it comes to NVDA… “acceleration cycles” are the keyExpert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.Use this link to see Nvidia Unchained right away! Get Neuren Pharmaceuticals alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume57,935 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewNeuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid, and in Phase 2 clinical trial for the treatment of Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.Read More… When it comes to NVDA… “acceleration cycles” are the key (Ad)Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.Use this link to see Nvidia Unchained right away! Receive NEU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neuren Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address NEU Stock News HeadlinesScott Power: S&P/ASX 200 Health Care Index falls but which stocks are up on positive news?November 15 at 2:14 AM | msn.comNeuren Pharmaceuticals’ Commitment to Neurodevelopmental CareNovember 15 at 2:14 AM | markets.businessinsider.comWhen it comes to NVDA… “acceleration cycles” are the keyExpert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.November 18, 2024 | DTI (Ad)Neuren Pharmaceuticals Unveils A$50 Million Share Buy-BackNovember 14, 2024 | markets.businessinsider.comBuy this ASX 200 share that is swimming in cashNovember 12, 2024 | msn.comCanaccord Genuity Remains a Buy on Neuren Pharmaceuticals Limited (NURPF)November 11, 2024 | markets.businessinsider.comASX 200 healthcare stock rockets on $75 million newsNovember 7, 2024 | msn.comNeuren Pharmaceuticals Reports Strong Q3 Financial GrowthNovember 7, 2024 | markets.businessinsider.comSee More Headlines NEU Stock Analysis - Frequently Asked Questions How were Neuren Pharmaceuticals' earnings last quarter? Neuren Pharmaceuticals Limited (ASX:NEU) posted its quarterly earnings data on Wednesday, February, 27th. The company reported $0.03 earnings per share for the quarter. Neuren Pharmaceuticals had a net margin of 60.66% and a trailing twelve-month return on equity of 75.51%. What other stocks do shareholders of Neuren Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Neuren Pharmaceuticals investors own include Oxford Lane Capital (OXLC), Pilbara Minerals (PLS), Sunrise Energy Metals (SRL), Westpac Banking (WBC), FBR (FBR), Embark Early Education (EVO) and Dream Industrial Real Estate Investment Trust (DREUF). Company Calendar Last Earnings2/27/2019Today11/17/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryChemicals Current SymbolASX:NEU CUSIPN/A CIKN/A Webwww.neurenpharma.com Phone61 3 9092 0480FaxN/AEmployees2,060Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A$0.93 Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$117.29 million Net Margins60.66% Pretax MarginN/A Return on Equity75.51% Return on Assets59.56% Debt Debt-to-Equity RatioN/A Current Ratio25.42 Quick Ratio31.54 Sales & Book Value Annual Sales$193.34 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow12.46 Book ValueA$1.72 per share Price / BookN/AMiscellaneous Outstanding Shares130,070,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta2.13 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (ASX:NEU) was last updated on 11/18/2024 by MarketBeat.com Staff From Our Partners5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredShocking footage from Bill Gates’ $100,000,000,000 AI BetIf you missed out on Nvidia, watch this video I just made.Brownstone Research | Sponsored🗓️ My First LIVE Event in 5 Years!Give us 60 minutes and we’ll show you how we’ve compressed 15 years of stock market gains into one day.Behind the Markets | SponsoredElon Musk’s $30 Billion Trump Bet Pays Off—What’s Next?Elon Musk bet big on Trump's victory, and that gamble has already added over $30 billion to his net worth in a...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuren Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Neuren Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
